

RECEIVED
CENTRAL FAX CENTER

FAX

JUL 28 2006



GlaxoSmithKline

To Attn: Examiner Deepak Rao , Group 1624
.....
Company USPTO
.....
Fax (571) 273-8300
.....
From Patty Wilson
.....
Tel 1-919-483-1007; Facsimile: 1-919-483-7977
.....
E-mail patricia.t.wilson@gsk.com
.....
Date July 28, 2006 Pages including cover 28
.....
Subject Application of: Andrews et al.
U.S. Serial No.: 10/070,084
Attorney Docket No. PU3517USw
.....

GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709

Tel: 919 483 2100
www.gsk.com

Attached: Response under 37 C.F.R. §1.111 (27 pgs.)

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Serial No. 10/070,084
Docket No. PU3517USw
Reply to Office Action of March 30, 2006

RECEIVED
CENTRAL FAX CENTER

JUL 28 2006

Docket No. PU3517USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Andrews, C.W. et al.

SERIAL NO. 10/070,084

ART UNIT: 1624

FILED: March 7, 2002

EXAMINER: Deepak R. Rao

FOR: BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE

Commissioner of Patents
P.O. Box 1450
Alexandria VA 22313-1459

Response under 37 C.F.R. § 1.111

Sir:

This Amendment is in response to the Office Action dated March 30, 2006 for which the period for response expired on June 30, 2006. Applicant hereby requests a 1 (one)-month extension of time to extend the response period up to and including July 30, 2006. Please charge Deposit Account No. 07-1392 in the amount of \$120.00.

In response to the Office action mailed March 30, 2006, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 25 of this paper.

07/31/2006 BABRAHA1 00000014 071392 10070084
01 FC:1251 120.00 DA